GlassScriptPhysician profile
Carol R Pinder
NPI 1154365476
$1,640.39
in general payments reported to CMS, 2019-2025
19 companies · $384 in 2025
The $384 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $261 · 2022: $325 · 2023: $347 · 2024: $324 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,017 · Education: $37.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,016.89 |
| Education | $37.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $386.37 | 2021-2025 | |
| Novo Nordisk INC | $286.41 | 2021-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $149.03 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $136.32 | 2021-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $120.89 | 2022-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $107.77 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $64.66 | 2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.15 | 2025 | Jardiance |
| Abbott Laboratories | $56.96 | 2023-2024 | Proclaim, Freestyle Libre 3 |
| Exact Sciences Corporation | $52.97 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.06 | 2024 | Xifaxan |
| Boston Scientific Corporation | $35.83 | 2024 | Wavewriter Alpha Prime 16 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.83 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $20.01 | 2022 | |
| Phadia US INC. | $19.22 | 2023 | Immunocap |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $17.56 | 2025 | Repatha, Otezla |
| Dexcom, INC. | $16.07 | 2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $15.58 | 2021 | |
| Paratek Pharmaceuticals, INC. | $13.70 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Pinder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.